Talking about tumor immunity to help precision medicine

In recent years, tumor immunotherapy, as a representative, has made a great breakthrough in tumor research and treatment Tumor immunotherapy is the fifth major therapy after surgery, radiotherapy, chemotherapy and targeted therapy With the rise of immunocheckpoint monoclonal antibody therapy and car-t cell therapy, the efficacy of immunotherapy has been gradually affirmed In 2013, Science Magazine selected tumor immunotherapy as the top ten scientific breakthroughs of the year In January 2016, ASCO annual report elected cancer immunotherapy as advance of the year In January 2016, based on the development of immunotherapy and targeted therapy, the United States proposed a cancer "moon landing plan" In March 2017, the "China anti cancer TIANTI plan" jointly launched by yuce biology and academician Zhan Qimin is the first genome cooperation plan specially launched for tumor immunotherapy in China On October 24, 2019, sponsored by yuce biology, CO organized by Broadway life and Health Industrial Park and life science and technology industry university research capital alliance, the tumor immunity seminar with the theme of "tumor immunity diagnosis and precision medicine" was successfully held in Shenzhen At the seminar, Zhang Cailian, chairman of dabihui life and Health Industrial Park, said that since the opening of dabihui life and Health Industrial Park, a series of enterprises in the forefront of life and health have gathered These enterprises mainly focus on gene detection, early screening of tumors, health management and other fields After several years of cultivation, they have initially formed a scale The enterprises represented by yuce biology and Siqin medical care stand out and become the star enterprises in the park Focusing on the characteristics and needs of life and health industry, the park provides enterprises with eight in one comprehensive services, including carrier, channel, capital and operation With the mission of "innovation and development empowerment of life and health industry", the park is based on Guangdong Hong Kong Macao Bay area, facing the international market, and combined with years of mature operation experience, to provide perfect platform support for industrial development It is hoped that the platform will gather more experts and scholars and have more opportunities for communication Dr Gao Zhibo, founder and CEO of yuce biology, first of all, thanks for the support of the big Baihui life and Health Industrial Park to yuce biology He stressed the importance of the research in the field of tumor immunity At the same time, he is very honored to invite Dr Yang Hongjun, CO chair of the precision medicine professional committee of China Institute of bioengineering He hopes that the outstanding enterprises in the park will come together to listen and discuss together About the development and future of tumor immunodiagnosis and precision medicine Expert speech Professor Yang Hongjun, CO director of precision medicine professional committee of China Institute of bioengineering, shared the speech with the theme of biomarker and precision medicine for cancer therapy At the same time, the author expounds his own opinions on biomarker and precision medicine of tumor treatment Professor Yang Hongjun pointed out that biomarker is of great significance for the accurate diagnosis and treatment of tumors, but the discovery of precise biomarker has a long way to go, especially in the field of tumor immunodiagnosis and treatment He also expressed his admiration for yuce biology's courage to challenge the field of accurate diagnosis and treatment of tumor immunity In the report of cell free DNA analysis for detection and monitoring of cancer, Dr Mao Mao Mao Mao, founder and CEO of Siqin medical, believed that by monitoring changes in the molecular level of free DNA, more accurate monitoring of efficacy and recurrence could be carried out after operation Recently, yuce has put forward the same idea in tumor targeting / immunodrug efficacy monitoring Dr Mao Mao Mao believes that with the efforts of all colleagues, the cancer diagnosis and treatment industry will surely find a broad-spectrum, accurate and cost-effective tumor monitoring program Liu Xiao, President of Huada health Application Research Institute, described the latest research results published in clinical science in the report entitled "human pan immune group plan and application", that is, T-cell receptor as a new diagnostic marker in autoimmunity of lupus erythematosus and rheumatoid arthritis The application of the disease and the pan immune group plan of the team were introduced in detail Through the cooperation of many parties, we hope to apply the research results to the clinical and large health fields in the future Dr Liu Qingbo, director of gene operation of Jingliang, shared the theme report of "establishment of large panel TMB standard", and Liu Qingbo This paper introduces the standard products of sudden change load, the testing process, testing content and application scenario of TMB, and explains the application of BTMB reference products of Jingliang as an example, aiming to establish the industry standard of TMB testing and contribute to the healthy development of the whole industry Yang Lin, director of yuce biological marketing department, made a report entitled "current situation and future of tumor immunodiagnosis" The report points out that with the clinical application of immune drugs becoming more and more extensive, the demand for immune biomarker is no longer limited to the screening of single drug sensitive population of immunosuppressive checkpoint inhibitors, and it is very important to find the markers of efficacy, drug resistance, toxicity, and even to guide the selection of combined treatment options Tumor Immunodiagnosis The essence is to explore the immune escape mechanism of every patient Later, Yang Lin reviewed the main therapeutic effects of immunotherapy related biomarker and TMB which caused a lot of hot discussion in the near future Based on the in-depth analysis of the principles of TMB and the therapeutic effects of immunotherapy, she triggered in-depth thinking about the predictive value and standard setting of TMB in immunotherapy, and proposed that neoantigen / TNB is the fundamental factor determining tumor immunogenicity HLA is the bridge between tumor genome and T cell response HLA LOH (loss of heterozygosity) reflects the coevolution of tumor cell and immune response It is necessary to analyze with TMB Yuce biology has done a lot of exploration work in the joint analysis of HLA and TMB Looking forward to the future, Yang Lin proposed a multi factor complexity based on the efficacy of immune drugs, and the ultimate ideal is to form a multi biomarker comprehensive evaluation model Let's talk about tumor immunity All the guests discussed the way out of accurate diagnosis and treatment of tumor immunity Experts believe that we need to conduct comprehensive analysis not only from the tumor itself, but also from the tumor microenvironment At present, TMB has a good effect in the prediction of single immunotherapy, but it is ineffective in the combination therapy At present, the combination therapy is lack of effective biomarker, which needs more trials and more evidence to track and verify Large panel can provide more complete information, not only in gene mutation, but also in tumor heterogeneity (ITH), HLA LOH, TNB and so on Of course, it is more significant for a large panel if it can be used as a concomitant diagnosis of drugs Nowadays, the strategic significance of the industry standard continues to improve under the multiple incentives of paying attention to relevant policies, regulations and rapid development of the industry in the field of tumor immunodiagnosis and treatment At the seminar, experts focused on "the way out of tumor immunoassay panel", "new technology trend of tumor precise immunodiagnosis and treatment", "formulation and standardization of new technology standard of tumor immunodiagnosis" and other topics, guided the new direction of tumor clinical diagnosis and treatment, and promoted the establishment of industry standard to become tumor The industry consensus of immunodiagnosis and treatment has even become the key development direction of IVD field (BIOON Com)